XTX Topco Ltd Has $575,000 Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

XTX Topco Ltd boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 84.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,897 shares of the company's stock after purchasing an additional 36,989 shares during the quarter. XTX Topco Ltd owned about 0.08% of Intellia Therapeutics worth $575,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after buying an additional 562,249 shares in the last quarter. Norges Bank bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $350,000. Wellington Management Group LLP increased its stake in Intellia Therapeutics by 8.5% in the fourth quarter. Wellington Management Group LLP now owns 699,814 shares of the company's stock valued at $8,160,000 after acquiring an additional 55,051 shares during the last quarter. Geode Capital Management LLC raised its position in Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock valued at $27,865,000 after purchasing an additional 45,930 shares in the last quarter. Finally, ExodusPoint Capital Management LP lifted its stake in Intellia Therapeutics by 98.4% during the fourth quarter. ExodusPoint Capital Management LP now owns 105,827 shares of the company's stock worth $1,234,000 after purchasing an additional 52,486 shares during the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Trading Up 0.8%

NASDAQ:NTLA traded up $0.09 on Thursday, reaching $11.46. 5,826,679 shares of the stock traded hands, compared to its average volume of 4,550,223. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $24.16. The company's 50 day moving average is $10.47 and its 200-day moving average is $9.50. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.19 and a beta of 2.31.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same period in the previous year, the business earned ($1.12) EPS. The firm's revenue was down 42.6% compared to the same quarter last year. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Activity

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at $1,486,989.24. The trade was a 6.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTLA. Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target for the company in a report on Monday, April 21st. Canaccord Genuity Group lowered their target price on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Guggenheim decreased their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Finally, Citigroup lowered their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.